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The complexity of cancer biology and its clinical manifestation are driven by genetic, epigenetic, 
transcriptomic, proteomic and metabolomic alterations, supported by genomic instability as well 
as by environmental conditions and lifestyle factors. Although novel therapeutic modalities are 
being introduced, efficacious cancer therapy is not achieved due to the frequent emergence of 
distinct mechanisms multidrug resistance (MDR). Advanced technologies with the potential to 
identify and characterize cancer MDR could aid in selecting the most efficacious therapeutic 
regimens and prevent inappropriate treatments of cancer patients. Herein, we aim to present 
technological tools that will enhance our ability to surmount drug resistance in cancer in the 
upcoming decade. Some of these tools are already in practice such as next-generation sequencing. 
Identification of genes and different types of RNAs contributing to the MDR phenotype, as well 
as their molecular targets, are of paramount importance for the development of new therapeutic 
strategies aimed to enhance drug response in resistant tumors. Other techniques known for many 
decades are in the process of adaptation and improvement to study cancer cells’ characteristics and 
biological behavior including atomic force microscopy (AFM) and live-cell imaging. AFM can 
monitor in real-time single molecules or molecular complexes as well as structural alterations 
occurring in cancer cells induced upon treatment with various antitumor agents. Cell tracking 
methodologies and software tools recently progressed towards quantitative analysis of the spatio-
temporal dynamics of heterogeneous cancer cell populations and enabled direct monitoring of cells 
and their descendants in 3D cultures. Besides, novel 3D systems with the advanced mimicking of 
the in vivo tumor microenvironment are applicable to study different cancer biology phenotypes, 
particularly drug-resistant and aggressive ones. They are also suitable for investigating new 
anticancer treatment modalities. The ultimate goal of using phenotype-driven 3D cultures for the 
investigation of patient biopsies as the most appropriate in vivo mimicking model, can be achieved 
in the near future. 
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 Cancers comprise various cell populations with distinct phenotypic and genotypic profiles 
as well as with an inherent potential for metastasis (Marusyk and Polyak, 2010). A recent definition 
describes cancers as epigenetic disorders where cells emerge and compete under a robust 
evolutionary pressure (Vitale et al., 2019).  The extracellular environment can produce a positive 
selection of subsets of pre-malignant cells with a fitness advantage towards metastasis and 
colonization of healthy tissues (Martincorena et al., 2017; Ostrow et al., 2014). Heterogeneity leads 
to the expansion of diverse niches, including hypoxic or perivascular regions that might support 
the development of cancer stem cell phenotypes and drug-resistant cell populations (Fu et al., 
2015; Junttila and de Sauvage, 2013; Mao et al., 2013; McGranahan and Swanton, 2017; Tellez-
Gabriel et al., 2016). 
 Cancer multidrug resistance (MDR) has been a subject of intensive research in the past 
four decades in an attempt to decipher the molecular mechanisms underlying MDR and develop 
novel modalities to surmount this major therapeutic impediment (Cui et al., 2018; W. Li et al., 
2016; Livney and Assaraf, 2013; Robey et al., 2018; Zhitomirsky and Assaraf, 2016). Still, the 
implementation of the significant amount of the generated findings in this field into clinical 
practice is rather insufficient. New emerging tools are necessary to address many burning 
questions regarding cancer MDR. Characterization of different MDR phenotypes (Assaraf and 
Borgnia, 1994; Goler-Baron et al., 2012; Goler-Baron and Assaraf, 2011; Ifergan et al., 2005; 
Zhitomirsky and Assaraf, 2017, 2015), correlation of their presence with cancer aggressive 
behavior and identification of new druggable targets to overcome MDR, are some of many 
important tasks in studying cancer MDR.  
Cancer is a complex disease that systematically affects the whole organism. Characteristics 
of cancer cells and their tumor microenvironment (TME) favor the progression of the disease and 
invasion of remote organs, distinct from the primary location of the cancer. These characteristics 
or hallmarks of cancer have been described and revised by Hanahan and Weinberg (Hanahan and 
Weinberg, 2011, 2000). In its latest revision, 10 characteristics of cancer were identified, the study 
the of which is hardly possible with classical two-dimensional (2D) cell culture methodology.  
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Cell-culture based screening of anticancer drug effects has significantly evolved in the past 
decades. For a long time, conventional 2D cell cultures have been employed as the sole in vitro 
model to test the anticancer activity of new drugs. In this respect, the NCI-60 human tumor cell 
lines screen using a panel of 60 human tumor cell lines of distinct cell lineage was introduced by 
the National Cancer Institute in Bethesda, MD, USA. These cytotoxicity studies on cells grown 
under monolayer conditions are quite affordable and easy to perform but have great disadvantages. 
Generally, these simple in vitro 2D models are unable to mimic the complexity of the tumor tissue 
and therefore their cytotoxicity results are rather different from those obtained in vivo (Pampaloni 
et al., 2007).  
 Animal models are important to study complex interactions with surrounding cells and 
tissues in cancer research. However, animal models including patient-derived xenografts, are far 
away from genuine tumors in cancer patients. Therefore, complementary methods capable of 
creating a complex in vitro microenvironment using microfluidic technology, have emerged. 
Three-dimensional (3D) cell cultures were introduced in anticancer drug screening to gain more 
valid in vitro data that could more faithfully represent the in vivo results of drug sensitivity. 3D 
culturing of human cells hence mimicking the conditions of the genuine tumors can surpass both 
practical and ethical obstacles in using animal models. Spheroids are the simplest 3D cell culture 
models that mimic cell-to-cell interactions and hypoxic conditions and therefore provide a more 
realistic drug response than conventional 2D cultures (Costa et al., 2016). However, spheroids still 
have some limitations primarily including the lack of extracellular matrix (ECM), with its complex 
physical and chemical characteristics (Valente et al., 2017). For that reason, various scaffold-based 
3D cell cultures were developed in recent years. They represent biocompatible 3D networks 
designed to provide structural support to the cells, with physicochemical characteristics that 
resemble ECM present in genuine tumor tissue (Hoarau-Véchot et al., 2018). Although these are 
more advanced 3D cultures, they are characterized by static conditions and lack fluid interstitial 
flow (i.e. blood) that is normally present in any tissue which significantly affects various 
phenotypes including response to cytotoxic drugs. 
 Other tools like next-generation sequencing (NGS) which has become irreplaceable in 
discovering mutations, gene expression and cancer biomarkers, offers a broad spectrum of 
possibilities for studying MDR (Chandana et al., 2019; Cho et al., 2019; Kyrochristos et al., 2019; 
Mi Li et al., 2015; Ming-hui Li et al., 2015). In the last years, high throughput NGS technology 
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revealed important findings regarding the genomic, epigenetic and transcriptomic diversity of 
cancers that otherwise would not be possible to acquire by standard histopathological analysis 
(Jiang et al., 2014; Teixeira et al., 2019; Turajlic et al., 2019). This is of paramount importance 
and clinical relevance especially for cancers displaying high levels of drug resistance (Røe et al., 
2012). 
 Some less common techniques such as atomic force microscopy (AFM) and single live-
cell imaging can facilitate the identification of MDR phenotypes in cancer patients’ specimens. 
AFM is a very versatile tool for biological research. Its multispectral capacity to monitor the 
topographical, mechanical adhesive and oscillatory patterns of living cells makes the instrument 
highly promising for cancer research and more specifically for drug development (Prusty et al., 
2018). On the other hand, the analysis performed by tracking single cells in a heterogeneous cancer 
cell population can determine the fate of each cancer cell while studying different characteristics 
including proliferative capacity, motility, shape, size, signaling patterns, and intercellular 
communication. 
 In this review we discuss the potential of i) NGS application in identification of cancer 
MDR as well as research covering DNA-based sequencing, RNA-based sequencing and clinical 
applications of NGS; ii) AFM application in cancer research and anticancer drug screening; iii) 
Single live-cell imaging applicability for the  identification of  drug-resistant and aggressive clones 
of malignant cells; iv) The use of microfluidics-based 3D cell cultures to evaluate cancer 
characteristics and complex interactions with its surrounding including blood flow as well as, v) 
Anticancer drug efficacy and mechanisms of resistance emerging under selective conditions that 
mimic the genuine tumor.  
 
2. Next-generation sequencing (NGS) in cancer MDR research 
  
 The rapid development of sequencing technologies for the human genome and 
transcriptome analysis has led to an enormous increase in our knowledge regarding the roles of 
genetic variability in various disorders including cancer. NGS technologies are useful in a broad 
spectrum of applications in biomedical research. These include a variant discovery by whole-
genome sequencing (WGS), whole-exome sequencing (WES) (Hitomi and Tokunaga, 2017) or 
targeted sequencing of genomic regions or gene panels of interest (Hlavac et al., 2018; Soukupova 
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et al., 2018; Wakai et al., 2019). RNA sequencing (RNA-seq) offers sequencing of the entire 
transcriptome and chromatin immunoprecipitation with sequencing (ChIP-seq) enables  
investigation of the epigenetic architecture of the genome (Rabbani et al., 2016). Other NGS 
applications include de novo assemblies of bacterial and eukaryotic genomes, species classification 
and/or gene discovery through metagenomics and DNA-Protein interaction analyses (Metzker, 
2010; Precone et al., 2015).  
Regarding MDR, NGS technologies allow us to identify DNA- and RNA-based molecular 
profiles associated with tumor development, progression and therapy outcome and thus recognize 
genetic determinants of MDR phenomenon in solid tumors (Chandana et al., 2019; Gov et al., 
2017; Kyrochristos et al., 2019; Verma and Sharma, 2018) and leukemia (Albitar et al., 2017; 
Bereza et al., 2017; Szankasi et al., 2016).  On the basis of ultra-deep sequencing, it is also possible 
to understand and combat the antibiotic resistome (Crofts et al., 2017; Hadjadj et al., 2019) and 
characterize in detail, drug resistance-associated mutations in pathogens and viruses causing 
serious diseases (Alidjinou et al., 2017; Gautam et al., 2019; Parker and Chen, 2017; Ramanathan 
et al., 2017; Soares et al., 2019; Thomson et al., 2016) as summarized in Fig.1. 
 
2.1. DNA sequencing  
 
 DNA sequencing opens new avenues in the study of tumor aggressiveness, allows 
comparative analyses between different population characteristic mutation rates (Saidijam et al., 
2015), evaluation of  DNA damage response and repair or telomere modification attributed to 
chemo- and radio-resistance (Nahar et al., 2018; Røe et al., 2012). The development of 
chemoresistance can arise due to either single or multiple drug applications. Sequencing or copy 
number analysis showed that the administration of multi-agent regimens leads to the development 
of MDR, which appears to be pathway-specific and not dependent on the combinations of 
mutations (Hammond et al., 2016; Pritchard et al., 2012). In addition, it is well established that 
drug resistance can be induced also after targeted therapies, and therefore the necessity for a change 
in clinical oncology treatment strategies is emerging (Masoud and Pagès, 2017; Pritchard et al., 
2012). Chemoresistance can be attributed to cancer cells with polyploidy, stemness phenotype or 
pro-inflammatory secretory phenotype as revealed by analysis of cDNA and mitochondrial DNA 
(mtDNA) (Ma et al., 2015; Rohnalter et al., 2015). 
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 DNA repair is an important mechanism in the development of drug resistance along with 
chromosomal aberrations, gene amplification, and genomic deletions. Moreover, a direct 
association between DNA methylation and MDR has been established (Chen et al., 2015; Kadioglu 
et al., 2016). DNA methylation status is gaining increased importance in the diagnosis of cancers 
since DNA methylation status can be examined in serum, urine or sputum of patients with 
neoplastic or pre-neoplastic lesions (Worm and Guldberg, 2002). 
 Complete genome sequencing helps in the identification of genes that contribute to MDR 
and consequently facilitates the decision as to which therapeutic regimen the patient will benefit 
the most (Hearn et al., 2018; Schröder et al., 2012). Thus, identification of co-mutations such as 
BRAF and NRAS supports the clinical practice which uses combinational therapy to target 
different pathways (Raaijmakers et al., 2016). Both DNA and RNA assays remain the basic 
methods through which the recurrent mutations are identified in most cancer types. However, 
combinations of epigenomic or genomic markers combined with proteomic biomarkers increase 
the therapeutic success rate, rather than utilizing just a single approach (Sinha et al., 2019). An 
example of multi-omics approach, is the combination of proteomics, transcriptomics and DNA 
interactome analyses which revealed a valuable information about mutant p53 proteins that have 
been discovered in more than 50% of human malignancies (Walerych et al., 2016), while the role 
of the mutated TP53 gene in drug resistance is still speculative (Alzoubi et al., 2016).  
 Importantly, some mutations can have a detection rate of up to 73%, when the tests are 
combined from different sources: circulating tumor DNA (ctDNA), biopsy and circulating tumor 
cells (CTC). Although differences between CTC and ctDNA genotyping and discordant genotypes 
between tumor biopsy and blood-based analyses were recognized, these disagreements are due to 
the methodological differences in isolation (Schechter et al., 2015; Sundaresan et al., 2016). Thus, 
it is known that the DNA isolation for a liquid biopsy varies due to tumor-specific mutations in 
DNA isolated from other cells present in the urine or the fluid itself (Mikhaylenko et al., 2018). 
   
 
2.2. RNA sequencing 
 
 RNA sequencing (RNA-Seq) technologies have been developed to analyze whole 
transcriptome profiles including gene expression profiles of protein-coding mRNA as well as non-
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coding RNAs such as microRNA (miRNA), long non-coding RNA (lncRNA) and circular RNA 
(circRNA) profiles (Costa et al., 2013; Ng et al., 2018; Nigita et al., 2019; Z. Wang et al., 2009). 
This technology has advanced predominantly in the last two years and it gradually replaces whole 
transcriptome arrays.  
 In MDR research, RNA sequencing facilitates the identification of transcriptional-based 
markers of acquired resistance, cancer progression, and treatment response (Ming-hui Li et al., 
2015; J. Wang et al., 2019; Xi et al., 2017). Besides, RNA sequencing can be used to study 
associations between genomic and transcriptomic alterations during tumor development, drug 
response and clinical outcome of patients. These changes can be associated with the development 
of drug resistance and differences in therapy outcomes (Cho et al., 2019). Whole transcriptome 
RNA sequencing can reveal the role of transcript deregulation and alternative splicing in malignant 
transformation and chemoresistance (De Laere et al., 2017; Goff et al., 2013) as described in Table 
1. RNAs devoid of coding potential referred to as non-coding RNAs (ncRNAs) have a great impact 
on molecular mechanisms, ranging from developmental processes to various diseases including 
cancer (Beermann et al., 2016; Tomar et al., 2019). ncRNAs are divided into two subclasses 
according to a relatively broad size threshold –miRNAs and lncRNA.  
 Small non-coding RNAs called microRNAs (miRNAs) are indeed approximately 21-23 bp 
long RNAs, which are involved in tumor development, progression and drug resistance through 
regulation of gene expression. Particular miRNAs such as miR-199a-5p and miR-222 were found 
to be associated with MDR of human colorectal cancer (Kong et al., 2012; Xu et al., 2012), while 
miR-27b modulates chemosensitivity of gastric cancer cells (Fang et al., 2016). The majority of 
miRNA profile studies were performed using microarrays. The recent development of RNA 
sequencing revealed new miRNAs (miR-7-5p, miR-22-3p, miR-483-3p) the gene targets of which 
were correlated with drug resistance in human cancers (Jia et al., 2019; Liang et al., 2019; Xiao et 
al., 2018).   
 Long non-coding RNAs (lncRNAs) can be associated with the development of 
chemoresistance of multiple types of cancer (Fang et al., 2016; Liang et al., 2018; Wang et al., 
2017; Wu and Wang, 2018). LncRNA transcriptome profiling has shown that lncRNAs are also 
involved in leukemia development, thus enabling the identification of different subtypes of human 
leukemia (Lammens et al., 2017). Taken together, through RNA sequencing, it is possible to detect 
and identify miRNAs, lncRNAs and their molecular targets as novel potential therapeutic 
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strategies to enhance drug response in resistant tumor cells as summarized in Table 1. Noncoding 
RNAs also play a critical role in the regulation of cellular DNA damage response (DDR) 
machinery, important for the prevention of tumorigenesis. ncRNAs can directly regulate processes 
involved in DDR by altering their target genes and DDR components. RNA sequencing 
technologies allowed the detection of interactions of ncRNAs with DDR components and render 
them as promising targets to overcome chemoresistance of tumor cells to conventional cytotoxic 
chemotherapeutics (Arjumand et al., 2018). 
 Circular RNAs (circRNAs) are a class of noncoding RNAs widely expressed in eukaryotic 
cells and characterized by their circular molecular configuration. CircRNAs were demonstrated to 
be potential regulators of miRNAs, transcription, and various protein functions. They can also 
encode for proteins, as previously reviewed (Hsiao et al., 2017; Yu and Kuo, 2019). The 
development of next-generation RNA sequencing technologies has allowed scientists to analyze 
the expression and composition of circRNA and elucidate their roles in pathological processes. 
CircRNA participates in the regulation of neuronal and cardiovascular diseases as well as in the 
regulation of cancer progression and drug resistance (Hsiao et al., 2017). Using RNA sequencing, 
circRNA expression profiles and their changes were identified in cancers including breast, lung, 
ovarian, endometrial, gastric, pancreatic, colorectal and hepatocellular cancer. Many associations 
of circRNA expression and circRNA-miRNA networks associated with drug resistance and cancer 
therapy outcomes, were found (Table 1). In addition, significant deregulation of circRNAs is 
correlated with drug resistance and therapy outcome of cancer patients. Bioinformatic analyses of 
circRNA expression identified mainly interactions with miRNA sequences (Chen et al., 2019; 
Huang et al., 2019). Identification of circRNAs using RNA-seq needs specific bioinformatic tools 
such as CIRexplorer (Galasso et al., 2016) or miARma-Seq (López-Jiménez et al., 2018) that can 
detect various associations and junctions of circRNAs with the transcriptome, miRNAs and other 
noncoding RNAs have been reported. In this respect, Kun-Peng et al., constructed circRNA-
miRNA-mRNA pathways related to circRNA hsa_circ_0004674 by TargetScan and miRanda 
tools (Kun-Peng et al., 2018). Optimal use of RNA-seq data is currently hindered by the short-read 
nature of the dominant sequencing technologies, which prevents completely reliable 
reconstruction and quantification of full-length transcripts. Thus, it is necessary to improve the 
detection of long reads during RNA-seq. This is precisely why direct, amplification-free 
sequencing of full-length RNA molecules is being introduced with the advent of nanopore 
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sequencing, which raises the possibility of yet another revolution in transcriptomics in the near 
future (Marinov, 2017). 
 
2.3. Targeted therapy and NGS 
 
 Tumor progression can be followed by relapse (Puig et al., 2008), due to a variety of 
genomic alterations, which render the cells chemoresistant, resulting in relapse. These studies 
suggest that a multistep pathway including DNA endoreduplication, polyploidy, followed by 
depolyploidization and generation of clonogenic escape cells can account for tumor relapse after 
initial efficacious chemotherapy. Therefore, the adaptation of new investigation strategies (Kumar 
et al., 2018; Siddiqui et al., 2018) such as testing patients’ plasma for epidermal growth factor 
receptor (EGFR) mutations is ongoing. Though, decision making in treatment strategies is 
supported nowadays by analysis of tumor DNA extracted from the plasma of cancer patients. 
However, a multitude of malignant pathologies still lacks biomarkers and those currently used 
reveal minimal benefits in classifying patients prior to chemotherapeutic treatment (Conteduca et 
al., 2017). 
 With emerging personalized targeted treatment strategies that take into consideration 
differences in tumor biology of different patients (Hu et al., 2015), novel clinical approaches such 
as plasmid DNA vaccination, improved tyrosine kinase inhibitors (TKIs)-based therapeutics 
(Leonetti et al., 2019; Sundaresan et al., 2016), as well as application of new chemosensitizers 
(Worm and Guldberg, 2002; Wu et al., 2014), the contribution of NGS became more valuable in 
both identification of cancer biomarkers and in selecting the most suitable anticancer treatment 
modality. 
 Although comparative analysis showed that droplet digital PCR (ddPCR) is more sensitive 
and also inexpensive, the advantage of NGS is in its capacity to monitor multiple gene mutations 
at the same time (Yang et al., 2016). Besides, some mutations can be determined using NGS from 
liquid biopsies (Mikhaylenko et al., 2018). Thus, NGS significantly contributes to the selection 






3. Atomic Force Microscopy (AFM) in cancer MDR research 
 
3.1. Atomic Force Microscopy in biomedical research 
 
 A novel tool appeared recently among the instruments used in cancer research: the atomic 
force microscope (AFM). This device was invented in 1986 by the Nobel laureate Gerd Binnig to 
image, at high resolution, electrically insulating surfaces (Binnig et al., 1986). Since the instrument 
can operate in liquids, it quickly became popular among biologists. Soon after, it appeared that not 
only does it permit to acquire high-resolution images of biological samples in nearly physiological 
conditions, but it can also explore their mechanical properties (Kasas and Dietler, 2008), detect the 
presence of specific molecules on its surface or monitor the sample’s metabolic rate. The device 
records all these data simultaneously and relatively simply, which qualifies AFM as promising 
research and diagnostic tool. 
 The AFM essentially consists of a sharp tip that scans the surface of the sample. The tip is 
fixed at the end of a soft cantilever that deflects accordingly to the topography of the scanned 
surface. The angular deflection of a laser beam that illuminates the cantilever end, permits to 
determine the vertical deflection of the lever very precisely, with a resolution that reaches 0.1 Å. 
Depending on the instrument’s manufacturer, the tip or the sample is attached to a piezo-electric 
scanner and is moved along the 3 axes under the control of electric signals sent by a computer. A 
computer generates a 3D image of the sample’s surface by displaying the cantilever deflection at 
each spot of the scanned sample. Fig. 2 displays the different imaging/data gathering working 
modes of the AFM that are of potential interest to cancer research and biomedical research.  
 The main motivation for AFM development was the high-resolution imaging of non-
conductive samples. The very first imaging mode implemented on these instruments is the so-
called contact mode since the tip is constantly in contact with the sample (Fig. 2A). However, it 
appeared very quickly that this mode is not appropriate to image weakly attached samples, such as 
individual proteins or DNA molecules. The lateral forces applied by the tip displace the sample 
and make it invisible to the AFM. To overcome this drawback, Zhong et al., developed the so-
called tapping mode (Fig. 2B) (Zhong et al., 1993). In this mode, the tip oscillates in the vertical 
axis and touches periodically the sample. In this imaging mode, the tip only applies a vertical force 
onto the sample, preventing its lateral displacement; it is therefore well adapted to image loosely 
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attached molecules. The third imaging mode is the so-called non-contact mode (Zhong et al., 1993) 
in which the tip is set to oscillate above the sample without touching it (Fig. 2C). The change in 
the cantilever oscillation frequency that occurs when the tip approaches the sample, serves to 
calculate the tip-sample distance. Therefore, this imaging mode virtually does not interact with the 
sample. However, its implementation is complex and is for the moment, restricted to a few 
laboratories in the world. 
The AFM measures mechanical properties by indenting its tip into the sample and 
monitoring the cantilever deflection during the process (Fig. 2D). The obtained curve, referred to 
as the indentation curve, displays the force that is needed to indent the tip to a given depth on the 
sample. Fitting the indentation curve with the appropriate model permits us to calculate the 
stiffness of the sample, assuming the shape of the AFM tip and some other parameters are well 
defined. A comprehensive and exhaustive study of this type of measurement can be found in 
Cappella and Dietler (Cappella and Dietler, 1999). 
 The detection of the presence of specific molecules expressed on the surface of the sample 
is achieved by attaching on the AFM tip a molecule that binds to the target (Fig.2E). By bringing 
the tip in contact with the sample, the two molecular species attach. During the retraction of the 
tip, the newly formed link deflects the cantilever downwards unless the cantilever restoring force 
overcomes the binding force between the two molecules. At this moment, the newly formed bond 
breaks and the cantilever returns to its rest position. The deflection of the cantilever before the 
bond breaks, multiplied by the lever spring constant, gives the interaction force between the two 
molecular species.  
 A variant of the classical tapping mode is the so-called Peak force-tapping mode. In this 
mode, the tip is set to oscillate at a low frequency and low amplitude to minimize the force applied 
onto the sample to tens of piconewtons. One single Peak force image contains information at a 
nanometric scale about the topography of the adhesion and the mechanical properties (elastic 
modulus, deformation, and dissipation) of the sample. 
 The last operating mode of the AFM consists of depositing the sample directly onto the 
cantilever (Fig. 2F). If the sample is alive, it induces nanometric scale oscillations of the lever that 
immediately stop as soon the organism dies. The technique is very new and permits to assess 
rapidly the sensitivity of bacteria to antibiotics. However, several pilot studies suggest its 
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usefulness in the field of cancer research and especially in the detection of anticancer drug 
resistance.  
 
3.2. Imaging of cancer cells 
 
 AFM imaging mode can be very useful in several fields of cancer research. The instrument 
can portray single molecules or molecular complexes in near-physiological conditions.  
Importantly, it also monitors the structural changes induced by different drugs in real-time. As an 
illustration, Alonso et al., monitored the topological modifications of DNA upon exposure to 
doxorubicin (Alonso-Sarduy et al., 2011). At somewhat lower magnification, ex vivo studies 
performed on lipid bilayers demonstrated the mechanism of action of anticancer drugs on cancer 
cell membrane rafts (Corsetto et al., 2012). This capability of the AFM is also applicable at a larger 
scale to single cells. It permits us to study the 3D topography of cellular membranes and partially 
the organization of uppermost components of the cytoskeleton. Numerous similar studies explored 
drug effects on the cellular membrane of the whole carcinoma, colorectal, lymphoma and breast 
cancer cells (Huang et al., 2012; M. Li et al., 2016; Venkatesan et al., 2010; J. Wang et al., 2009). 
Quantifying morphological changes affecting 3D surfaces such as cellular membranes as seen by 
AFM can be very challenging. Simple roughness measurements are not sensitive enough to 
highlight subtle changes. Analyzing the fractal dimension of the cellular surface could be a 
valuable alternative to distinguish subtle differences occurring after drug treatment (M. 
Starodubtseva et al., 2017; M. N. Starodubtseva et al., 2017; Starodubtseva et al., 2019). All these 
data strongly suggest that following online cell surface changes upon drug action can help in 
distinguishing sensitive from resistant cancer cells. 
 
3.3. Studying mechanical properties of cancer cells 
 
 Numerous links were made in the last decade between alterations of the mechanical 
properties of cells and pathological states. Among the studied diseases, cancer is certainly the one 
that focused most on the attention of AFM users. The majority of studies demonstrated that cancer 
cells are softer than normal cells whereas some, such as hepatocellular cancer cells, cervical 
carcinoma cells, myeloid and lymphoid leukemia cells were reported stiffer than their normal 
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counterparts (Ding et al., 2015; Lekka, 2016; Rosenbluth et al., 2006; Zhang et al., 2002). The 
reasons for these modifications are still unknown and subjected to debate (Rianna et al., 2018). 
During invasion and metastasis formation, cancer cells need to rearrange their cytoskeleton to exert 
enough force to break down intercellular contacts, start to move and follow their path through the 
extracellular matrix. These rearrangements inevitably modify the mechanical properties of the 
cells, since the actin cytoskeleton was demonstrated to play a major role in the determination of 
the cellular mechanical properties (Kasas et al., 2005).  Modifications occurring in cancer not only 
affect cells but extend also to the extracellular matrix, which changes its stiffness and adhesive 
properties. The extracellular matrix not only sustains and connects cells but also influences 
numerous cellular functions (Ulrich et al., 2009). It is also documented to modulate cellular 
mechanical properties (Solon et al., 2007). By considering the mechanical properties alterations 
that are occurring in both, cells and extracellular matrix, it becomes possible to distinguish by 
AFM cancerous tissue from the normal one (Plodinec et al., 2012). The sensitivity of cancer cells 
to drugs can also be explored by monitoring cellular mechanical properties. Sharma et al. noticed 
a significant difference in the mechanical properties of cisplatin sensitive and resistant ovarian 
cancer cells (Sharma et al., 2012).  The authors attributed the difference to changes in the actin 
cytoskeleton. Further studies led by Seo et al., confirmed that the acquisition of cisplatin resistance 
by ovarian cancer cells induces a reorganization of the actin cytoskeleton (Seo et al., 2015). Similar 
studies were carried on the prostate, and B-lymphoma cancer cells under various chemotherapeutic 
conditions and demonstrated that chemotherapeutic treatments induce an increase in the stiffness 
of the cells (Mi Li et al., 2015; Ren et al., 2015). These studies suggest that mechanical properties 
can be used to discriminate in a close future sensitive from resistant cell types.  AFM could be 
included in the diagnostic instrumentation chain. A comprehensive recent review of 
nanomechanical fingerprinting of cancer can be found in Stylianou et al., (Stylianou et al., 2018). 
 
3.4. Studying adhesive properties of cancer cells 
 
 Xiao et al., demonstrated in 2013 that not only the mechanical properties of cancer cells 
are useful to monitor cellular response to chemotherapy but also their adhesive properties (Xiao et 
al., 2013). The team compared non-small cell lung cancer cell lines (A549) with non-cancerous 
human primary small airway epithelial cells. The AFM measurements revealed an increased 
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stiffness and increased adherence of the non-cancerous population. Brief exposure to doxorubicin 
for 4 h in lung cancer cell lines highlighted an increase of adherence and stiffness of the cancer 
cells and an opposite modification of both parameters in the non-cancerous cells. This study 
indicates the potential of using cell adhesion modifications to assess drug activity in cancer cell 
lines.  
 More specific adhesive properties can also be explored by AFM by tracking single miRNA 
molecules. miRNA deregulation is observed in cancer and several cardiovascular and neurological 
diseases (Gebert and MacRae, 2019; Lujambio and Lowe, 2012).  It was demonstrated that the 
levels of certain miRNA can even predict cancer prognosis (Shell et al., 2007). Thus, miRNA 
quantification emerged quickly as an important topic in the field of cancer research. AFM 
contributes to the development of this research field by detecting the miRNA in single cells without 
reverse transcription or amplification. The measurement consists of fixing cells, removing their 
plasma membrane and scanning the remaining cell components with a DNA probe attached to the 
tip and that is complementary to the specific miRNA (Koo et al., 2016). This type of investigation 
can be very useful to assess drug activity at the single-cell level and it can be speculated that 
miRNA monitoring can be a useful marker in the detection of drug resistance. 
 
3.5. Characterization of extracellular vesicles by AFM 
 
 In recent years, the capacities of the AFM were applied to explore the abundance, the 
morphology as well the mechanical properties of exosomes and other extracellular vesicles. These 
organelles have a diameter in a range between 30 and 120 nm and mediate a multitude of 
intercellular communications (Yamamoto et al., 2019). They exhibit several surface-bound 
proteins and receptors. The cargo of extracellular vesicles consists of proteins and genetic material 
such as miRNA, mRNA proteins and DNA molecules. They are present in several body fluids 
such as blood, cerebrospinal fluid, saliva, urine, and amniotic liquid (Rahbarghazi et al., 2019). 
These organelles play an important role in numerous infectious diseases, neurodegenerative 
processes, and cancer (Jan et al., 2019). Compared to the traditional investigation tools such as 
optical and electron microscopy, AFM presents an interesting exploration tool to characterize these 
organelles. It can operate in a nearly physiological environment and investigate the extracellular 
vesicle abundance, morphology, mechanical properties, and biomolecular content. Extracellular 
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vesicles monitoring during chemotherapy could be an additional marker for treatment efficiency. 
A comprehensive review of the potential use of  AFM in the field of extracellular vesicles was 
recently published by Sharma et al., 2018 (Sharma et al., 2018). 
 
3.6. Using nanomotion to discriminate cancer MDR cells 
 
 It was also demonstrated that AFM-based detection of nanomotion can monitor the life-
death transitions of single cells upon exposure to cytotoxic drugs (Longo et al., 2013). The 
technique is essentially employed for bacteria antibiotic sensitivity tests. The test lasts a dozen of 
minutes and is label-free. The method can be extended to cancer research to determine the 
sensitivity or resistance of cancer cells to anticancer drugs. The first experiments made with cancer 
cells (Kasas et al., 2015) were rapidly and successfully reproduced by other independent research 
teams. Wu et al. monitored the action of paclitaxel on the oscillation pattern of breast cancer cell 
lines (MCF-7) (Wu et al., 2016). Expectedly, the amplitude of oscillations dramatically dropped 
after the injection of the drug in the analysis chamber. The technique is relatively simple, can apply 
one to dozens of cells simultaneously and importantly, is completely label-free. In terms of 
sensitivity, in these preliminary experiments, the authors solely monitored life-death transitions. 
However, the technique is sensitive enough to follow subtler metabolic rate changes such as those 
occurring during cytoskeletal rearrangements. It, therefore, can potentially highlight subtler drug-
induced effects on the cytoskeleton hence paving the way towards novel avenues for cancer 
research.  
  
4. Single live-cell tracking for identification of drug-resistant and aggressive cancer cells 
 
 Single live-cell imaging has become widely used to study cancer particularly when it can 
address intra-tumor and inter-tumor heterogeneity and complexity. Various cell tracking 
methodologies and software tools progress towards quantitative analysis of the spatio-temporal 
dynamics of heterogeneous cell populations present in tumors. However, direct monitoring 
(tracking) of many initial single cells and their descendants during several days in realistic 3D 
tumor environments has so far not been technically feasible. Developments in lens-free 
microscopy may change this situation (Berdeu et al., 2018). Label-free single-cell tracking in 3D 
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space is not currently feasible combined with subsequent biochemical analyses of individually 
tracked cells while keeping their track identity.  2D single-cell tracking can more easily supplement 
subsequent biochemical analyses and act as surrogate measurements for the 3D situation. Holo-
tomographic microscopy (HTM) may here provide high-resolution ground-truth and facilitate 
tracking of cellular organelles during shorter periods inside an otherwise sparse sampling regime. 
HTM is label-free, non-phototoxic microscopy analyzing the fine changes of a cell’s refractive 
indices (RIs) in 3D. Hence, by combining HTM with epifluorescence, one can show that cellular 
organelles including lipid droplets and mitochondria show a specific RI signature that 
distinguishes them with high resolution and contrast. Hence, HTM may allow following the 
dynamics of mitochondria, lipid droplets as well as that of endocytic structures in live cells and 
beyond (Sandoz et al., 2018). However, the tracking of intracellular organelles normally requires 
both high resolution and image sampling rates that in principle could create phototoxicity and heat. 
One may assume that long term rapid high-resolution sampling for thousands of cells would 
produce an unmanageable amount of data. This in principle may not be true if the analysis takes 
place in real-time (“on the fly”) and only accumulated data from analyses are stored. This approach 
has conceptual similarity to so-called compressive sampling where sensor data are compressed 
while measurements take place. 
 The advance of applications of single-cell tracking is likely to actualize a need for the 
design of new cell lines to improve the selection of experimental cells that are fit for tracking and 
analysis.  For example, some types of cells tend to clump together complicating and restricting 
practical long term tracking.  Stably transfected cell lines can help solve this problem. These cells 
are transfected with fluorescently tagged proteins that are commercially available. The use of 
chromobody technology is another alternative to visualize the localization and dynamics of cellular 
targets for drug screening and trace cellular processes (Traenkle and Rothbauer, 2017). 
 Tracking of single live cells growing as monolayers currently gave more precise insight 
into cellular dynamics and cell fate decisions as compared to still images taken from fixed cells 
(Cooper and Bakal, 2017). It provides more possibilities to explore critical biological events in 
cell populations, such as proliferation, migration, differentiation, cell death or to reveal rare or 
emergent cell sub-populations (Gascoigne and Taylor, 2008; Gómez-Villafuertes et al., 2017; 
Korsnes and Korsnes, 2018; Moussy et al., 2017; Piltti et al., 2018; Shaffer et al., 2017). 2D single-
cell tracking is still considered technically challenging due to many experimental settings to be 
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considered such as cultivation conditions of distinct cell populations, appropriate cell culture 
density, changes in individual cell morphology, light conditions, imaging frequency, adjustment 
of focusing and lack of software tools (Al-Kofahi et al., 2006; Coutu and Schroeder, 2013; 
Meijering et al., 2012; Schroeder, 2011). The majority of approaches for cell tracking has been 
based on cell segmentation or frame-to-frame linking of segmented organelles (Coutu and 
Schroeder, 2013; Meijering et al., 2012; Schroeder, 2011).  Fluorescence-based long term tracking, 
although commonly used, may produce phototoxicity or unwanted artifacts (Gómez-Villafuertes 
et al., 2017; Milan et al., 2016). Further advancement of lens-free microscopy may open new 
avenues for automatic 2D-based single-cell tracking (Rempfler et al., 2018).   
 Single-cell tracking can complement other single-cell analyses such as DNA/RNA 
sequencing. However, to achieve maximum combined benefit from both technologies, it is 
imperative that those cells previously monitored by time-lapse are later re-identified and 
individually collected for the secondary analysis (Gómez-Villafuertes et al., 2017). This can be 
achieved by using microscopes including positional coordinates, by applying fluorescent reporters 
for specific cells or by using chambers with labeled grids that can identify individual cells as 
references (Gómez-Villafuertes et al., 2017). Automatic recognition based on relative positions 
between cells is also a possible approach to re-identify cells. 
 Single-cell tracking combined with other end-point analyses such as indirect 
immunofluorescence has been useful to identify proteins of interest or cell division markers. Cell 
tracking has so far been mainly based on semi-automatic visual guidance/control or tailored 
recording equipment (Sato et al., 2018, 2016). There are currently only a few published results 
based on systematic single-cell tracking for several days showing a complete lineage tracing using 
standard equipment for video recording (Korsnes and Korsnes, 2018, 2017, 2015).  Several studies 
claim the production of automatic single-cell tracking based on computer vision algorithms 
(Akram, S.U. et al., 2017; Huth et al., 2010; Tinevez et al., 2017). However, their contributions 
lack illustrations evidencing a complete lineage tracing from their recordings (Al-Kofahi et al., 
2006; Davis et al., 2007; Errington et al., 2005; Khan et al., 2007; Sato et al., 2018, 2016). The 
presently available tools for single-cell tracking are missing methodology to resolve ambiguities 
such as joint multi-target tracking and classification (Hilsenbeck et al., 2016; Hormoz et al., 2016; 
Rapoport et al., 2011; Stadler et al., 2018). However, the development of software tracking tools 
is under constant improvement (Davis et al., 2007; Errington et al., 2005; Khan et al., 2007; Koh 
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et al., 2017; May et al., 2018). The latest advancements appear to focus on automation based on 
localized image analysis and recognition. Statistics from cell lineages (pedigree trees), feature 
extraction and identification of inheritance of traits, can contribute to discover and to resolve 
tracking ambiguities and thereby contribute to a holistic approach for cell tracking. 
 
4.1. Proxy measurements from 2D light microscopy recordings  
 
 The purpose of single-cell tracking from 2D light microscopy recordings is not to mimic 
how they may behave at various complex environments but rather reveal the inherent properties 
of cells. Experiments with 3D-models can presumably help to utilize results from 2D-models for 
the improved prognosis of cancer. Conceptually simple single-cell tracking from 2D light 
microscopy recordings can provide proxy observations of inheritance of traits via measurements 
of cells related via pedigree trees. It can also provide information related to the process of cell 
division as well for example the tendency of cellular senescence for subgroups of cells due to 
treatments. New information is in general available when measurements from cells can be related 
to lineages. 
 The following list indicates actual types of observables from 2D light microscopy 
recordings and their possible biological relevance:  
 Parameters from movements. A Levy flight model may fit single-cell tracking data (Huda 
et al., 2018). It can reflect a change in the persistence of directions of movements caused 
by a change in the cytoskeleton and cell shape. Stress often tends to affect the movements 
and motility of cells.   
 Changes in cell shape can correlate with its signaling history and state (Cooper and Bakal, 
2017). 
 Vacuolization and vacuole inheritance may play an important role in cell death and 
survival. 
 Nuclear changes based on tracking and extracting features from fluorescent-labeled nuclei 
(Bolgioni et al., 2018; Cooper et al., 2017). 
 Variation in the size of pedigree trees for a population can indicate heterogeneity and 
potential for long term change in the composition of cells (Korsnes and Korsnes, 2018). 
The non-symmetric shape of pedigree trees increases the likelihood of mitotic failures. 
20 
 
 Correlation of cell death modalities between sister cells indicates signaling downstream 
pedigree trees (Korsnes and Korsnes, 2018).  
 The time from observed onset of mitosis until actual cell division. 
 The time between subsequent events of mitosis. 
 Mitotic cell fate (Bolgioni et al., 2018). 
 Changes in the texture of cell images can indicate cytoskeleton disruption or membrane 
rupture. 
 Parameters from cell rounding (duration, size, and shape). Improper cell rounding may 
indicate mitotic failure (Lancaster et al., 2013). 
 Contact between cells can affect them and their descendants. 
 Correlations between physical contact and movements (a tendency for cells to stick 
together). Cells may need time to transfer information between them.  
 Correlations between movements and physical contact between cells may increase the 
likelihood of intercellular influence.   
 Synchronization of cell division among adjacent cells. Synchronous cell division may 
indicate intercellular communication. 
 Cell rounding and its duration during mitosis. If there is no proper cell rounding or its 
duration is outside the normal range, then chromosomal instability may take place 
(Lancaster et al., 2013). 
In general, the above observables will depend on treatments and cultivation conditions. Big 
data analyses can support the extraction of usable knowledge from such exhaustive and 
presumably weakly related data. In addition, it can be used to perform data mining utilizing 
extensive databases containing results from many similar experiments with various toxic 
exposure and cell types. 
Korsnes and Korsnes demonstrated correlations between parameters derived from the 
movements of sister cells using the computer program KoBio Celltrack 
(https://korsnesbiocomputing.no) (Korsnes and Korsnes, 2018). They also showed correlations 
between cell death modalities for sister cells following changes in cell morphology. The program 
visualizes search for correlations resulting in hypothesis formulation. Fig.3 is an example of such 
visualization; it shows A549 non-small cell lung cancer cells exposed to the marine toxin 
yessotoxin (YTX) at a concentration of 500 nM. The tracks of two pairs of sister cells followed 
21 
 
during 0-10 h after the division of their mothers are superimposed on Fig.3A. Fig. 3 also includes 
corresponding pedigree trees for these sister cells (Fig.3B, C). The cells belonging to the small 
pedigree tend finally to die (Fig. 3C) and move significantly faster than the thriving cells belonging 
to the large pedigree tree (Fig.3B). This recording led to the idea that observation of movements 
may serve as a proxy for cellular stress and inheritance (and potentially cell death in mitosis or 
mitotic catastrophe for some cells). 
Such observations of correlations can be used for many purposes. Drug treatment of cells 
can affect inheritance. This implies that changes in inheritance can be considered as a response to 
drug treatment. Measurements of inheritance of traits may also be used for technical quality control 
of tracking as well as control of cell cultivation. Inheritance of signatures related to movements 
also has an interest in the identification of sub-populations and their level of cellular stress. 
 
5. Microfluidic technology to study the MDR phenotype in cancer 
 
 The microfluidic technology for cell culture applications, also known as organ-on-chip, 
designs and fabricates microfluidic devices made of silicones, glass or thermoplastic materials 
(polystyrene, cyclic olefin copolymer or similar) that are structured with cameras and channels to 
fit the cell scale. This scale allows the recreation of complex multicellular architectures (3D 
cultures surrounded by epithelial barriers and/or vascular networks, etc.) and the mechanical and 
chemical physiological environment in a well-controlled manner. Important hallmarks of cancer 
and/or its TME including hypoxia, cell invasion/metastasis, and angiogenesis which can be 
simulated in vitro using microfluidic chips are highlighted in Fig. 4. These micro-physiological 
systems have been used to mimic some of the most relevant characteristics of tumor progression 
and metastasis, while cellular changes and adaptations to different environmental conditions can 
be easily monitored in real-time under the microscope (Hachey and Hughes, 2018; Shang et al., 
2019; Sontheimer-Phelps et al., 2019).  
 
5.1. Studying proliferative characteristics of cancer cells 
 
 One of the fundamental characteristics of tumor progression and metastasis is sustained 
proliferation mediated by deregulated signaling pathways accompanied by a lack of response to 
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growth suppressor signals. The utility of microfluidic devices to study these processes has been 
described recently (Hassell et al., 2017). A decrease in EGFR and phosphorylated EGFR levels 
was observed in lung cancer cells subjected to mechanical stress which was used to simulate the 
respiration process inside a microfluidic device. To achieve this, the authors designed a 
microfluidic device with two chambers separated by a porous and deformable membrane inducing 
the mechanical stimuli over the cells in a physiological manner. Another example has been 
described by Lang et al., who constructed a device that confronted different cell types (breast 
cancer cells and stromal fibroblasts) to facilitate intercellular communication (Lang et al., 2013). 
However, they revealed that the modified expression of estrogen receptors in breast cancer cells 
was not related to the heterotypic cell-cell contact. The proliferation rates of MCF-7 cells were 
responsible for the observed changes in the estrogen receptor expression. Another example of how 
microfluidic devices could simulate complex physiological proliferation processes was recently 
described (Ayuso et al., 2017). Proliferation was observed only in glioblastoma cells that had 
migrated in response to an oxygen gradient. In this case, microfluidic devices were manufactured 
to be impermeable to gases, forcing all the nutrients and oxygen to reach the central chamber with 
cells embedded in 3D hydrogel through the perfused lateral channels. When only one lateral 
channel was perfused, the cells far from the perfused channels migrated towards higher oxygen 
concentrations. No cell proliferation was observed when both lateral channels were perfused or 
during the migration process. Glioblastoma cells proliferated exclusively once they reached the 
oxygen-rich area. 
 
5.2. Studying changes in cellular metabolism 
 
 The TME is characterized by heterogeneous zones with different physicochemical 
characteristics like chemical (cytokines, nutrients or oxygen) or physical gradients (stiffness). The 
generation of these gradients can be achieved in multiple ways in a microfluidic device 
(Somaweera et al., 2016). To study the effect of nutrient and oxygen gradients, Ayuso et al., 
cultured glioblastoma and colorectal cancer cells in a microfluidic device that is not permeable to 
gases in which, due to the high cell density, zones of self-induced ischemia were created by cellular 
metabolism (Ayuso et al., 2016). In these metabolically heterogeneous models, cancer cell 
sensitivity to different chemotherapeutic drugs was assessed demonstrating variations in their 
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effect due to the metabolic location of cancer cells. Moreover, the deregulation of the cellular 
energetic mechanisms present in the TME can induce the production of reactive oxygen species 
(ROS). The oxidative state, modulated by the antioxidant coenzyme Q10, and its relation with the 
cell death and resistance mechanisms have been studied by Burić et al., in a glioblastoma model 
(Burić et al., 2019). A significant increase in temozolomide sensitivity upon combined treatment 
with coenzyme Q10 was observed in drug-resistant glioblastoma cells located in the highly 
oxygenated zone of the microfluidic chip when compared to the hypoxic area. 
 
5.3. Studying tumor metastatic behavior  
 
 Several reviews and research articles have recently reported different approaches that 
simulate the process of tumor metastasis using microfluidics (Caballero et al., 2017; Lee et al., 
2016; Portillo-Lara and Annabi, 2016; Sleeboom et al., 2018; Sontheimer-Phelps et al., 2019). Hao 
et al., described invasion profiles of different breast cancer cell phenotypes in newly formed bone 
tissue inside a microfluidic device (Hao et al., 2018). Fluorescent MDA-MB-231-BRMS1GFP cells 
showed no significant interactions with the osteoblastic tissues formed on-chip. However, in co-
culture with osteoblastic tissue, MDA-MB-231GFP cells increased their invasive capacity. This 
study opened the door to the phenotypic characterization of circulating breast cancer cells to 
predict the probability of bone metastasis occurring in breast cancer patients. On the other hand, 
several research groups have also developed multi-organ microfluidic chips to study tropism 
toward other organs which is characteristic of some cancers. Along this line, Alemán et al., 
corroborated in vitro the preference of colorectal cancer organoids to metastasize to liver and lung 
tissues (Aleman and Skardal, 2019), while Xu et al., undertook similar studies by demonstrating 
the tropism of lung cancer cells to nervous, bone, and liver tissues (Xu et al., 2016). Another 
approach in studying metastasis - vascular interaction with the tumor cells was explored 
(Boussommier-Calleja et al., 2019; Chen et al., 2017). Thus, Boussommier-Calleja et al., described 
the role of monocytes in the extravasation of tumor cells in 3D vasculature models inside 
microfluidic devices (Boussommier-Calleja et al., 2019). Reduction in trans-endothelial migration 
mediated by soluble factors released by monocytes was observed. However, macrophages derived 
from circulating monocytes showed no significant effect on extravasation processes. Moreover, 
the formation of new blood vessels has been also simulated in microfluidic devices (Haase and 
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Kamm, 2017). Several microfluidic designs have been employed to mimic the angiogenic process. 
Lee et al.  described that the presence of U87 glioblastoma cells was able to markedly increase the 
sprout numbers and coverage areas of the microvessels compared to cancer cell-free controls (Lee 
et al., 2014). Agarwal et al., embedded cancer cells in alginate capsules to recapitulate the 3D 
structures (Agarwal et al., 2017). In a posterior step, those capsules were assembled with other 
cells from the TME (endothelial and stromal cells) to resemble a macroscale 3D vascularized 
tumor. Their results showed a very significant increase (between 4.7- to 140-fold) in drug 
resistance to doxorubicin when compared to the 2D culturing method. Other research groups have 
focused their research to test the impact of antiangiogenic drugs using microfluidic devices, 
providing new applications of this technology to combat cancer, particularly against 
chemoresistant tumors (Kim et al., 2015).  
 
5.4. Studying interactions with the immune system  
 
 Immune system cells are also present in the TME where their role has been modulated or 
compromised by the tumor cells (Pardoll, 2012). Therefore, modulation of the immune response 
is considered a promising therapeutic strategy and recently immune-tumor interaction was 
evaluated in microfluidic chips (Aref et al., 2018; Moore et al., 2018). Namely, small specimens 
of patient biopsies were placed in the interior of microfluidic chips to assess the efficacy of immune 
checkpoint inhibitors. In addition, recently approved personalized therapy with genetically 
modified CAR-T cells was also tested in a biomimetic environment on-chip by using co-culturing 
of liver cancer cells with CAR-T cells (Pavesi et al., 2017). Co-culture was performed within a 
microfluidic device capable of controlling the environmental conditions such as the oxygen levels 
and the presence of inflammatory cytokines. 
 It is well established that inflammation affects several hallmarks of cancer and its role in 
carcinogenesis and cancer progression has been well established (Coussens and Werb, 2002; Kon 
and Benhar, 2019; Taniguchi and Karin, 2018; Todoric and Karin, 2019). Being a complex process 
mediated by several cell types of the TME, inflammation is not possible to study in-depth with 
classical culturing methods. Therefore, several approaches using different microfluidic devices to 
mimic the immune-cancer interactions were developed (Boussommier-Calleja et al., 2016). A 
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promising design to study damage-associated molecular patterns after post-ischemic inflammation 
has been reported (Ayuso et al., 2016).  
  
6. Microfluidic-based 3D cell cultures for drug screening 
 
 The development of microfluidic technology and its application in designing microfluidic-
based 3D cell cultures have made breakthroughs in overcoming drawbacks in evaluating anti-
cancer drug sensitivity/resistance in vitro.  
  
6.1. Drug resistance in microfluidic-based 3D cultures 
 
 3D cultures are generally more resistant to chemotherapeutics than monolayer cultures (Jo 
et al., 2018); this particularly refers to microfluidic-based cultures. In recent years, several research 
groups have reported this phenomenon. Ozcelikkale et al., 2017 used their TME-on-chip (T-
MOC), to mimic drug transport in tumor tissue (Ozcelikkale et al., 2017). They observed that two 
breast carcinoma cell lines with different molecular profiles (MCF-7 and MDA-MB-231) were 
both more chemoresistant to doxorubicin (free or nanoparticle-loaded) in T-MOC than in 2D 
cultures. Moreover, triple-negative breast cancer cells, MDA-MB-231, displayed increased 
resistance compared to MCF-7 in the T-MOC platform. The authors revealed that the absence of 
eIF3a was one of the major mechanisms of drug resistance in both cell lines grown in the 
microfluidic chip, while overexpression of the hyaluronic acid receptor CD44 in the MDA-MB-
231 cell line appeared responsible for its increased chemoresistance in T-MOC. In another 
microfluidic device, a butterfly-shaped microchip developed by Yildiz-Ozturk and colleagues, 
MCF-7 and MDA-MB-231 cells were also more resistant to doxorubicin and the antioxidant 
carnosic acid, than in a 2D culture system (Yildiz-Ozturk et al., 2017).  
 Uhl et al. showed that human colorectal cancer cells HCT116 were more resistant to 
conventional chemotherapeutics doxorubicin, paclitaxel, and capecitabine when grown as tumor 
spheroids within the bi-layer microfluidic system (Uhl and Liu, 2019). Another research group 
compared the responsiveness of the same cells to 5-fluorouracil, oxaliplatin, vincristine, and 
sorafenib in their “tumor-on-a-chip” platform and 2D culture, showing increased resistance to all 
tested drugs in a microfluidic device (Sobrino et al., 2016).  
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 Another study reported that both sensitive and MDR breast carcinoma cell lines, MCF-7S 
and MCF-7R, were more resistant to doxorubicin in the microfluidic system compared to 2D 
monolayer (Sabhachandani et al., 2019). Interestingly, in 3D perfusion systems, sensitive and 
drug-resistant cell lines had almost the same response to doxorubicin at lower drug concentrations 
(1 µM and 5 µM), while drug-resistant cells become more resistant only at higher doxorubicin 
concentrations (10 and 20 µM)(S. Wang et al., 2019).  
 3D microfluidic-based cultures are also more resistant to cytotoxic drugs than static 3D 
cultures (Pradhan et al., 2018; Yildiz-Ozturk et al., 2017). These differences in drug response in 
3D models point to the significance of the presence of media and drug flow in cell culture systems 
for a more clinically relevant evaluation of anticancer drug efficacy.  
 It is interesting to note, unlike other authors, that Jo et al., observed that glioblastoma T98G 
cells displayed a better response to doxorubicin in microfluidic chip compared to other static 3D 
cultures and even 2D cultures (Jo et al., 2018). Detailed analyses revealed that in perfusion culture, 
cells were almost completely removed by media flow due to their loss of cell adhesion and 
attachment ability upon doxorubicin treatment.   
 Importantly, it was shown that data obtained from microfluidic devices on drug 
responsiveness of both breast carcinoma and bladder cancer cell lines established from patients are 
similar to those collected from the corresponding in vivo experiments, thus confirming the validity 
of the use of microfluidic-based cultures in anticancer drug screening (Gheibi et al., 2017; 
Ozcelikkale et al., 2017). 
 Microfluidic technology can be also useful to separate cells based on their intrinsic 
characteristics, including cell size. Therefore, several microfluidic devices were developed to 
investigate the effect of different cell/spheroid size on drug susceptibility (Pang et al., 2016; Patra 
et al., 2016; Zuchowska et al., 2017). Two groups reported that both single cells and spheroids of 
smaller size, are more resistant to the tested drugs, vincristine, and 5-fluorouracil, respectively 
(Pang et al., 2016; Zuchowska et al., 2017). However, according to the study of Patra et al., the 
effect of spheroid size on drug response depends on the type of applied drug; smaller HepG2 tumor 
spheroids are more sensitive to cisplatin, while the cytotoxic effect is opposite for resveratrol and 
tirapazamine treatments (Patra et al., 2016). 
 




 The presence of various physicochemical conditions and distinct cellular components in 
tumors, significantly affect the response to chemotherapy (Table 2). Microfluidic technology 
enabled us to introduce these tumor-related factors in cell cultures under controlled settings and to 
monitor their impact on drug response in a single device. 
 Hypoxia present in tumor tissue is one of the major TME conditions contributing to 
chemoresistance. Thus, its presence in 3D culture is essential to obtain more clinically relevant 
results on drug cytotoxicity. Microfluidic technology provides a platform for adjusting the oxygen 
level to perform more accurate in vitro drug screening. Li and colleagues designed a microfluidic 
chip which generates an oxygen gradient (Li et al., 2018). They confirmed its feasibility for drug 
screening on SF767 glioma cells and NSCLC A549 cells using two drugs differentially active 
under hypoxic conditions, tirapazamine and bleomycin. Another research group developed a 
microfluidic device to study drug resistance development under different oxygen levels (Germain 
et al., 2016). They showed that hypoxia-induced a rapid acquisition of drug resistance in prostate 
cancer cells, PC3, to staurosporine within 30 min, but this effect was reversed after switching to 
normoxic conditions. 
 The presence of media flow in microfluidic devices enables studying the effects of shear 
stress (normally present in tumor tissue) on drug toxicity, which is not possible to examine in other 
in vitro experimental settings. A study on a microfluidic device with two different continuous flow 
rates revealed that cultured ovarian cancer SKOV-3 cell spheroids developed resistance to cisplatin 
and paclitaxel. This shear stress-induced chemoresistance was mediated by increased expression 
of ATP-Binding Cassette (ABC) transporters, P-glycoprotein (ABCB1) and Breast cancer 
resistance protein (ABCG2), that was not observed under static conditions (Ip et al., 2016). 
 Apart from fluid shear stress, the mechanical effects of physiological movements could 
also be studied in microfluidic-based 3D cultures. Hassel et al. developed lung cancer-organ-on-
a-chip that incorporates different cells, malignant (human H1975 lung adenocarcinoma cells) and 
non-cancerous (human primary alveolar epithelial cells and human lung microvascular endothelial 
cells), and which mimics physiological breathing motions (Hassell et al., 2017). The authors 
showed that breathing motions contributed to the resistance of EGFR mutated cells to a tyrosine 
kinase inhibitor, a phenomenon commonly noticed in NSCLC (Leonetti et al., 2019). The observed 




6.3. Drug screening in microfluidic-based 3D co-cultures 
 
 The application of microfluidic platforms is particularly suitable for establishing 3D co-
cultures of two or more cell types (Table 2). Microfluidic technology, with constant fluid 
perfusion, provides the appropriate spatial organization of different cell lines, therefore mimicking 
their normal physiological interactions. This is particularly important for the evaluation of drug 
cytotoxicity and studying the microenvironmental effects on drug sensitivity in 3D in vitro 
systems.  
 Several studies have shown that co-culturing cancer cells with fibroblasts in microfluidic 
devices induced cancer cell resistance (Jeong et al., 2016; Sabhachandani et al., 2016; Yang et al., 
2018), and at the same time increased sensitivity of fibroblasts to tested drugs (Jeong et al., 2016; 
Sabhachandani et al., 2016). Jeong and colleagues proposed that this effect in colorectal tumor 
spheroids could be at least in part due to their increased fibronectin expression that coincides with 
the reduced drug uptake (Jeong et al., 2016).  
 Excluding fibroblasts, endothelial cells also contribute to the resistance of cancer cells in 
3D microfluidic-based co-cultures (L. Lin et al., 2017). According to Lin et al., , resistance of 
cervical carcinoma cells to paclitaxel in the presence of human umbilical vein endothelial cells 
(HUVECs) in microfluidic chip, is associated with higher cell viability, increased expression of 
angiogenic proteins and active redox system (low ROS and high GSH level) (L. Lin et al., 2017).  
 Pericytes are another tumor-associated cell type that contributes to the chemoresistance of 
cancer cells in microfluidic co-culture. It was shown that spheroids of primary lung 
adenocarcinoma epithelial tumor cells co-cultured with primary pericytes are less responsive to 
cisplatin perfusion than PLETCs monoculture (Ruppen et al., 2015) 
 Different non-malignant cell types exert different effects on cancerous cells in 3D 
microfluidic co-cultures. Mi and colleagues showed that tumor-associated macrophages and 
monocytes contribute more to the survival of breast carcinoma cell lines in response to paclitaxel 
treatment in the microfluidic device when compared to epithelial cells (Mi et al., 2019). 
 To study paracrine interactions that confer resistance of BRAF mutated melanoma cells to 
the BRAF inhibitor, vemurafenib, Patel et al., developed a microfluidic device for co-culture pairs 
of sensitive and drug-resistant cells (Patel et al., 2015). They demonstrated that in response to 
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vemurafenib, drug-resistant cells exert a protective effect on sensitive cells. This effect was 
mediated by FGF-2/FGFR signaling and reactivation of the MAPK pathway downstream of 
BRAF. 
 Scientists and engineers have gone even a step further and developed several models of 
tumors/organs-on-a-chip that are comprised of complex co-cultures of malignant cells and multiple 
non-cancerous tumor-associated cells, such as endothelial cells, epithelial cells, immune cells and 
fibroblasts (Du et al., 2018; Nguyen et al., 2018; S. Wang et al., 2019). These 3D microfluidic 
systems authentically mimic complex tumor structures and multicellular interactions and therefore 
are valuable platforms for more reliable preclinical drug testing. For example, Wang and 
colleagues have shown that MCF-7 breast carcinoma cells are more resistant to doxorubicin in the 
microfluidic chip when cultured with spatially organized endothelial cells and fibroblasts than 
without these cells (S. Wang et al., 2019). 
 
6.4. Single and multiple drug evaluation in microfluidic-based 3D cultures 
 
 An important aspect of every drug screening process is defining the most appropriate drug 
concentration/dose that will exert the expected cellular response. Microfluidic-based 3D cultures 
have found their application in this part of the drug discovery process as well. Several research 
groups have developed different microfluidic platforms for culturing cancer cells in a drug 
concentration gradient (Han et al., 2016; Lim and Park, 2018; K. Lin et al., 2017; Lin et al., 2019), 
therefore making a step forward towards rationally selecting personalized therapeutic drug dose.  
 These microfluidic systems, that generate spatial drug concentration gradient in long-term 
cultures, also allow studying the development and mechanisms underlying drug resistance.  In two 
independent studies, the authors showed that prostate epithelial cancer PC3 cells and glioblastoma 
U87 cells were initially eliminated in the region of high drug concentration in microfluidic chips 
with the spatial drug concentration gradient. However, cancer cells soon repopulated this area due 
to the emergence of a drug-resistant cell sub-population and its migration to high drug 
concentration region  (Han et al., 2016; K. Lin et al., 2017). Han et al. extracted these resistant 
U87 cells, which repopulated the Cancer Drug Resistance Accelerator chip upon doxorubicin 
treatment, and revealed that increased drug efflux activity was the main cause of their doxorubicin 
resistance (Han et al., 2016). They also performed exome and transcriptome sequencing and 
30 
 
identified several mutated genes (CHD1 and FLNA) related to doxorubicin resistance, as well as 
a significant number of differentially expressed genes associated with immune response, 
doxorubicin metabolism and NF-κB signaling. In a recent study by Lin and colleagues (Lin et al., 
2019), the authors revealed that PC3 cells moved from low to high docetaxel concentration regions 
in which these cells were transformed into polyploid giant cancer cells, known as major mediators 
of therapy resistance in prostate cancer. To distinguish drug-sensitive and drug-tolerant/resistant 
cells, Pandya et al., developed a microfluidic device with an electrical sensing component which 
measures electrical conductivity changes after cell lysis in response to hydrodynamic drug flow 
(Pandya et al., 2017). As a cell model for system feasibility testing, they used B16-F10 mouse 
melanoma, 4T1 mouse breast cancer, and DU 145 human prostate cancer cells and treated them 
with carboplatin or paclitaxel, depending on the cell type.  
 Except for single anticancer drug testing, microfluidic-based 3D cultures are also suitable 
for the evaluation of combined drug effects, which represents a common chemotherapeutic 
approach in cancer treatment. Generally, microfluidic devices for multiple drug applications are 
designed to generate a concentration gradient of drug combinations, therefore making them useful 
for the optimization of combination drug treatment. For example, An et al. developed a 
microfluidic chip that generates 64 different concentration combinations of curcumin and tumor 
necrosis factor-alpha (TNFα) related apoptosis-inducing ligand (TRAIL) and tested them on PC3 
cells (An et al., 2014). A different design of microfluidic chip was used by Fan et al., to examine 
the cytotoxic effect of 24 different concentration combinations of pitavastatin and irinotecan 
against the human glioma U87 cell line (Fan et al., 2016). The same group, in the recent study, 
improved this brain cancer chip by preventing any drug molecule diffusion between channels. The 
validity of the new system was tested on glioblastoma patient-derived spheroids with simultaneous 
exposure to temozolomide and bevacizumab (Akay et al., 2018). Most recently, Khoo and co-
authors evaluated the combined effect of doxorubicin and aspirin in eliminating cancer stem cells 
responsible for chemoresistance (Khoo et al., 2019). They used a microfluidic array with a gradient 
generator component that mixes drugs and makes various drug concentration combinations.   
 Microfluidic-based 3D cultures could be also successfully used to evaluate the potential of 
different compounds to overcome MDR. As previously mentioned, Burić et al., recently reported 
the sensitization of resistant RC6 cells to temozolomide by its combining with coenzyme Q10 in 




7. Future directions in cancer MDR research 
 
 Future techniques that could explain the complex interaction between resistance 
mechanisms and TME can help to develop efficient personalized treatment strategies. The use of 
phenotype-driven 3D cultures for the investigation of patient-derived biopsies could be optimal 
for the establishment of the most appropriate in vivo mimicking model. Answering the key 
question of which cancer patients could benefit from the specific therapeutic regimen, should be 
prioritized in primary tumors’ treatment to avoid the development of metastatic disease. To that 
end, the construction of biomimetic devices with advanced characteristics may facilitate the 
precise manipulation of culturing conditions and sustainable maintenance of complex 
environmental milieu. 3D printing and microfabrication can yield scaffolds with various 
geometries, thus enabling spatial investigation of cancer cells co-cultured with stromal cells 
embedded in the specific ECM. Importantly, controlled transport of nutrients and oxygen, as well 
as hormones and growth factors, can provide the establishment of relevant signaling patterns in 
cancer cells that could not be achieved with traditional 2D culture. Besides, 3D culturing in 
bioreactors will secure long-term follow-up of cancer progression and treatment efficacy, thus 
overcoming the problem of inconsistency between the length of tumor growth in patients and 
tumor growth under in vitro culture conditions. Namely, phenotypic alterations occur during the 
time in a certain chronology and thus real-time monitoring should replace endpoint analyses. This 
will further contribute to the development of the organ-on-chip platform. One of the most 
successful examples is the tissue engineering of human skin for modeling human melanoma 
growth (Netzlaff et al., 2005). Even pharmacokinetic studies that have been exclusively performed 
in animal models were successfully accomplished in devices equipped with channels and chambers 
enabling culturing of liver, lung and fat cells in interconnected compartments with an exchange of 
metabolites  (Esch et al., 2011). It seems rational that microfluidic devices can be adjusted for 
high-throughput screenings of patient samples to identify chemoresistant phenotypes and to define 
the most efficacious treatment regimens. This research direction will certainly favor the 
understanding of phenotypic changes while intracellular mechanisms could be left aside. Shifting 
the focus of cancer research that was for many decades directed towards studying complex 
signaling networks and pathways, may lead to the unravelling of key cancer research mysteries. 
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On the other hand, heterogeneity among cancer cells calls for their individual analysis to identify 
resistant and aggressive malignant clones. Heterogeneity increases the likelihood of the 
development of drug-resistant subpopulations which can be critical for the progression of cancer. 
The way to achieve the most accurate and efficacious treatment which is the administration of 
potent drugs to each patient, requires the characterization of cancer cell phenotypes as well as 
molecular profiles. The recent upgrading and continuous improvement of sophisticated sequencing 
tools at the single- and multiple-cell level enhance our knowledge about the molecular context of 
tumor behavior and interaction with its surroundings. Through new sequencing tools deciphering 
the molecular mechanism, underlying cancer drug resistance can help in the design of more 
efficient and precise chemo- and radiotherapeutic strategies. Targeted therapies were developed 
upon the identification of biomarkers derived from primary tumor biopsies subjected to genomic 
sequencing. In the future, more attention should be given to the disease in its relapsed stage and 
the utilization of sequencing techniques for the modification of initially used treatment regimens. 
 It was previously shown that cancer cells exhibit different motility patterns with the ability 
to shift between an epithelial to mesenchymal (i.e. amoeboid) mode to enable the invasiveness and 
dissemination of cancer cells (Wolf et al., 2003). Therefore, studying the motility of cancer cells 
using modern imaging tools can provide additional information about cancer cell behavior in 
association with 3D platforms. Recently, different AFM models have been created mainly to study 
the mechanical and dynamic properties of cancer cells (Cartagena-Rivera et al., 2015; Dufrêne et 
al., 2017; Guan et al., 2017). Coupled with the abovementioned complementary techniques, AFM 
can help to answer unresolved issues in cancer research including the interplay between drug 
resistance and metastatic disease. Continuous interest in the development and improvement may 
give AFM technology an important role in cancer research, diagnosis, and therapeutics. 
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Table 1. Examples of using RNA sequencing technology in identification of MDR phenotype in human cancer 
RNA RNA sequencing technology Effects and clinical applications Reference 
Coding RNA;    
 Targeted RNA sequencing of 
Androgen receptor (AR) in 
liquid biopsies (n = 34) from 30 
patients with castration-resistant 
prostate cancer 
Comprehensive  AR profiling revealed  associations of AR 
alterations  with endocrine treatment outcome in patients 
with castration-resistant prostate cancer 
De Laere et al., 2017 
 
 RNA sequencing in patients with 
colorectal cancer (n=35) and 
multi-organ metastases 
Alterations in gene expression profiles during tumor 
metastatic development are associated with development of 
MDR and therapeutic outcome in colorectal cancer 
Cho et al., 2019 
 RNA sequencing of MCF-7 and 
MCF-7/MDR breast cancer cell 
lines 
Analysis and identification of differentially expressed 
genes and associated signaling pathways involved in 
development of resistance in sensitive MCF-7 and MCF-
7/MDR breast cancer cells (e.g. NOS3 and BDNF genes) 
Yang et al., 2016 
 RNA sequencing of CCRF-CEM 
and resistant CEM/ADR5000 
leukemia cell lines 
Except well-known MDR associated genes such as 
ABCB1, many new genes were found to be differentially 
regulated in MDR cells (ABCG2, ABCA2, Apoptosis 
genes, Transcription factor genes, Heat shock genes, 
Kinase genes, Receptor genes, Oxidative stress genes) 
Kadioglu et al., 2016 
 
 RNA sequencing of gefitinib-
sensitive (PC9 and H292) and 
gefitinib-resistant (PC9/GR and 
Gene expression profile of 48 human ABC transporters in 
gefitinib-resistant PC9/GR and H292/GR cells were 
examined using RNA-seq and compared with that of the 




H292/GR) non-small cell lung 
cancer cell lines 
parental cell lines and ABCC10 was found to have an 
important role in acquired resistance to gefitinib in non-
small cell lung cancer 
Non-coding 
RNA; 
   
miRNA miR-omic and RNA-sequencing 
of five bladder cancer cell lines 
miR-22-3p was selected as a target, which promotes 
bladder cancer resistance by targeting NET1 
Xiao et al., 2018 
 
 Small RNA sequencing and 
transcriptome sequencing of 
oxaliplatin-resistant colorectal 
cancer cell line HCT116/L and 
its parental cell line HCT116 
miR-483-3p was involved in the regulation of oxaliplatin 
resistance in human colorectal cancer cells through its 
functional target FAM171B 
Liang et al., 2019 
lncRNA RNA sequencing data from 456 
colorectal tumors compared to 
normal samples 
Potentially oncogenic lncRNA SNHG15 was found to be 
involved in promoting colon cancer and mediating drug 
resistance 
Saeinasab et al., 2019 
 
 LncRNA sequencing of the 
ovarian cancer cell line A2780 
and the paclitaxel resistant cell 
line A2780/PTX 
5 up-regulated and 21 down-regulated lncRNAs are 
considered as the multidrug-resistant lncRNAs. The 
multidrug resistant genes ABCB1, ABCB4, ABCC3, and 
ABCG2 are all co-expressed with lncRNA CTD-
2589M5.4. 
Xu et al., 2018 
 
 RNA-sequencing at high depth 
sequencing in primary follicular 
lymphoma samples ranging from 
grade 1-3A to aggressive grade 
LncRNAs have been differentially expressed across the 
clinico-biological spectrum of follicular lymphoma with the 
top deregulated lncRNA called RP4-694A7.2 potentially 
involved in cell proliferation 




3B variants using unpurified 
(n = 16) and purified (n = 12) 
tumor cell suspensions from 
nodal samples 
circRNA RNA sequencing of cisplatin-
sensitive and cisplatin-resistant 
gastric cancer cells from humans 
Thousands of distinct circRNAs were revealed in cisplatin-
sensitive and cisplatin-resistant gastric cancer cells from 
humans. CircRNA termed circAKT3, was significantly 
upregulated in cisplatin-resistant gastric cancer tissues and 
cells. circAKT3 modulated cisplatin sensitivity by 
sponging miR-198. 
Huang et al., 2019 
 
 circRNA expression profiles in 
normal and malignant 
esophageal epithelial cell lines 
by RNA sequencing 
813 significantly up- and 445 down-regulated circRNA 
candidates were found to be associated with pathways 
involved in metabolism, cell apoptosis, proliferation and 
migration. Interaction circRNA-miRNA network were 
constructed. 
















Drugs  Major findings Reference 
 
Double-layer  
microfluidic chip with 
membrane that uses chemical 












normoxia caused resistance 
to  tirapazamine 
Li et al., 2018 
 
Microfluidic 







acquisition of resistance 
within 30 min, with 
reversible effect 
Germain et al., 2016 
 
Microfluidic device with 
continuous, well-defined, 










by increased expression of 
ABCG2 and P-glycoprotein 
Ip et al., 2016 
 
Microfluidic organ-on-a-chip  












Hassel et al., 2017 
 
Droplet based microfluidic 









fibroblasts induced cancer 
cell resistance 
Sabhachandani et al., 
2016  
 
4 units microfluidic chip each 
unit with 7 channels 
 







increased  fibroblasts 
sensitivity 
Jeong et al., 2016, 
 
non-small cell 
lung cancer  
fetal lung 













Integrated microfluidic device 
with three individual 
components for co-culturing, 











co-culture showed higher 
chemoresistance  
L. Lin et al., 2017  
 
Microfluidic device for 
homogeneous spheroid 






primary pericytes cisplatin 
higher chemoresistance in 
primary co-culture 
spheroids compared to 
primary monoculture 
spheroids 

























monocytes  more contribute 
to chemoresistance than 
epithelial cells 
Mi et al., 2019 
 
Microfluidic device with two 









A-375 – drug 
resistant 
vemurafenib 
resistant cells increased 
chemoresistance of 
sensitive cells by paracrine 
signaling 
Patel  et al., 2015 
Microfluidic device 
integrating 4 cell populations 
with a central 
endothelium compartment  















CAFs contributed to 
resistance  
 
























cells were more resistant 
when cultured in the 
microenvironment 





Fig. 1. Application of NGS in studying MDR. 
 
Fig. 2. Different imaging and analysis modes of the AFM. The sample is depicted in red. The 
arrows indicate the cantilever displacement direction. In blue: control electronics imposed motion. 
In red: displacement induced by the living organisms present on the cantilever (subfigure F). (A) 
Contact, (B) Tapping, (C) Non-contact, (D) Force spectroscopy to measure the sample’s stiffness, 
(E) Force spectroscopy to measure molecular interaction forces, and (F) Nanomotion. 
 
Fig. 3. Single live-cell tracking analysis. (A) Image of live A549 non-small cell lung cancer cells 
exposed to 500 nM yessotoxin (YTX) showing tracks of two pairs of sister cells after cell division. 
Black dots in the trajectory curves represent 1 h of displacement (total track 10 h). (B) Pedigree 
tree of thriving cells. (C) Pedigree tree of stressed cells. 
 
Fig.4. Hallmarks of microfluidic chips application in cancer research. 
 
